Key Takeaways:
- Revenue of $32.6 million beat consensus of $29.9 million by 8.9%
- EPS loss narrowed to $0.01 from a $0.0587 estimate
- Q2 results mark continued momentum for the handheld ultrasound maker
Quay lại
Butterfly Network beats Q2 estimates on $32.6M revenue, narrower EPS loss
Butterfly Network reported Q2 revenue of $32.6 million, beating consensus of $29.9 million, with EPS loss narrowing to $0.01.
The company's handheld ultrasound platform continues to gain traction in point-of-care settings, with revenue exceeding analyst projections by $2.7 million. The company did not disclose forward guidance in its earnings release.
Revenue of $32.6 million came in 8.9 percent above the $29.9 million consensus. The EPS loss of $0.01 compared with the $0.0587 loss analysts had projected, a $0.0487 per-share improvement. The results mark continued progress toward profitability as the company scales its portable ultrasound devices against larger competitors including GE HealthCare and Philips.
Butterfly Network, which trades on the NYSE under the ticker BFLY, has built its business around a single-probe, whole-body ultrasound system designed for use across emergency departments, primary care, and remote settings. The company's Q2 performance reflects sustained demand for its handheld devices, though year-over-year revenue comparisons were not disclosed in the release.
The beat comes as the broader medical imaging market continues to shift toward portable and accessible diagnostic tools. Traditional ultrasound leaders GE HealthCare and Philips have expanded their own handheld offerings, intensifying competition in the point-of-care segment. Butterfly's ability to exceed consensus estimates suggests its software-enabled approach and subscription-based business model are resonating with clinical customers.
The narrower loss signals improving operating leverage for the medical device maker. Investors will watch the company's earnings call for updated guidance and any commentary on adoption trends across its clinical customer base.
This article is for informational purposes only and does not constitute investment advice.
